TY - JOUR T1 - COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW JF - medRxiv DO - 10.1101/2020.05.01.20087494 SP - 2020.05.01.20087494 AU - Aline Pereira da Rocha AU - Alvaro Nagib Atallah AU - Ana Carolina Pereira Nunes Pinto AU - César Ramos Rocha-Filho AU - Felipe Sebastião de Assis Reis AU - Keilla Martins Milby AU - Vinicius Tassoni Civile AU - Nelson Carvas Junior AU - Rodolfo Rodrigo Pereira Santos AU - Laura Jantsch Ferla AU - Giulia Fernandes Moça Trevisani AU - Gabriel Sodré Ramalho AU - Maria Eduarda Santos Puga AU - Virgínia Fernandes Moça Trevisani Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087494.abstract N2 - CONTEXT AND OBJECTIVE We propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42020179863Funding StatementThis study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior‐Brasil (CAPES)‐ Finance Code 001Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article ER -